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Effect of BG-4 on  OVCA cell proliferation 
Figure 1. BG-4 purified from Momordica
chrantia caused dose-dependent
cytotoxicity in COV318 OVCA cells. BG-4treatment led to a decrease in viable cellcount by 19.8% at 250 μg/mL. Mean valuesrepresented as bars with different letter(s)are statistically different from each other(P<0.05, n=2).
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Figure 2. BG-4 purified from Momordica
chrantia caused dose-dependent
cytotoxicity in 1AP (A27801AP) OVCA cells.BG-4 treatment led to a decrease in viable cellcount by 65.1% at 250 μg/mL. Mean valuesrepresented as bars with different letter(s)are statistically different from each other(P<0.05, n=2).
Figure 4. BG-4 modified expressions of cell cycle proteins in 1AP OVCA cell








BG-4 induces apoptosis in OVCA 1AP cells as measured by flow cytommetry.Quantification of OVCA cells undergoing apoptosis as a result of BG-4 treatment. Thelive cells were from 89.955% (untreated) to 73.92% and 68.83% for 125 μg/mL and250 μg/mL treatment, respectively. Early apoptotic cells were from 7.10%(untreated) to 20.99% and 23.95% for 125 μg/mL and 250 μg/mL treatment,respectively. Late apoptotic cells were from 1.965% (untreated) to 3.72% and 5.37%for 125 μg/mL and 250 μg/mL treatment, respectively. Necrotic cells were from0.98% (untreated) to 1.36% and 1.81% for 125 μg/mL and 250 μg/mL treatment,respectively. Mean values represented as bars with different letter(s) are statisticallydifferent from each other (P<0.05, n=2).Figure 3. BG_4 modified expression of apoptotic proteins. (a) BG-4 promotedapoptosis by increasing caspase-3 (a) and BAX (b) leading to a reduced expression of
XIAP (c) and no change in expression of Bcl-2 (d). Mean values represented as bars
with different letter(s) are statistically different from each other (P<0.05, n=2).
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